2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1446

The Optimal Joint Set for Ultrasound Assessment of Synovitis in RA: Results from the Rasch Measurement Model

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1194

The Physiological Changes of the Enthesis in Response to Age, Body Mass Index and Physical Activity: An Ultrasound Study in Healthy People

Imaging of Rheumatic Diseases Poster II: Ultrasound

9:00AM-11:00AM: Abstract Number: 1505

The Point-of-Care Ichroma Anti-CCP Test Showed a Competitive Measurement Accuracy, in Comparison to the Conventional Automated Tests

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1040

The Potential Role of Choline Kinase Alpha in Osteoarthritis

Osteoarthritis and Joint Biology – Basic Science Poster I

9:00AM-11:00AM: Abstract Number: 1150

The Potential Uses of an Infodemiology Approach for Health-Care Services in Rheumatology

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1479

The Predictive Utility of Anti-Cyclic Citrullinated Peptide Antibodies to Diagnose Rheumatoid Arthritis in Patients with Hepatitis C and Polyarthralgias

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1131

The Prevalence and Incidence of Gout, Its Associated Comorbidities and Treatment Pattern: An Epidemiological Study from Germany

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1511

The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1374

The Relationship between Loneliness and Osteoarthritis in US Adults from a Nationally Representative Survey

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1300

The Relationship between Metabolic Syndrome Severity and the Risk of Mortality in Gout Patients: A Population Based Study

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1774

The Relationship between Serum Cholinesterase, Dickkopf-1 and Number of Organ Involvement in Japanese Patients with IgG4-Related Disease

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1402

The Relationship of Pain, Fatigue and Emotional Distress with Quality of Life in Juvenile Myositis

Patient Outcomes, Preferences, and Attitudes Poster I: Patient-Reported Outcomes

9:00AM-11:00AM: Abstract Number: 1567

The Risk Factors and Prognosis of Interstitial Lung Disease Associated with Primary Sjogren’s Syndrome: A Multi-Center Cohort Study

Sjögren's Syndrome – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1167

The Role of Fear-Avoidance Model on Pain and Disability in Knee Osteoarthritis Patients

Epidemiology and Public Health Poster II – ARHP

9:00AM-11:00AM: Abstract Number: 1433

The Role of Patient and Parental Resilience in Amplified Musculoskeletal Pain Syndrome

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].